Delivery Order SPE2DR25D9239-SPE2DR26FFBJ9
- Not listed
- The Defense Logistics Agency awarded a $77,830.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order was issued on October 20, 2025, with an ultimate completion date of November 10, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This...
- The Defense Logistics Agency awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a targeted pharmaceutical procurement to support Department of Defense healthcare operations. The award carries no set-aside...
- The Defense Logistics Agency awarded a $27,343.62 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, represents a focused procurement action without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $31,900.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 420 mg/14 mL vials of Perjeta, an oncology treatment medication. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The contract, awarded on September 15, 2025, carries a ceiling value of $27,343.62 and utilizes firm fixed-price pricing with an ultimate completion date of October 6, 2025. This delivery order was issued without a set-aside designation, enabling DMS Pharmaceutical Group to...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc. on September 22, 2025, for the supply of Perjeta 420 mg/14 mL vials totaling $27,343.62 with firm fixed pricing. This delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA valued at $499,999,999 and effective through November 2026. The award carries no set-aside designation and requires completion by October 14, 2025, with performance based in Park Ridge,...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, valued at $9,114.54 with a firm fixed-price structure, was awarded on September 23, 2025, with an ultimate completion date of October 15, 2025. This delivery order was issued without a set-aside designation, leveraging the vendor's competitive standing as a...
- The Defense Logistics Agency (DLA), operating under the Medical Supply Chain, awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc. on September 16, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order is scheduled for completion by October 7, 2025, with performance taking place at the contractor's location in Park Ridge, Illinois. The award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete directly...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth up to $25,529.76 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 4563969889 - Perjeta 420 mg/14 ml vial, 14 ml, with a performance period through April 1, 2024. This delivery order is issued under DMS Pharmaceutical Group's indefinite delivery contract SPE2DB24FSW68 with DLA, which has a ceiling value of up to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $63,801.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a specific supply requirement fulfilled under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The...
- SPE2DR25D9239Indefinite Delivery Contract
- SPE2DR25D9239-SPE2DR26FFBJ9Delivery Order
The Defense Logistics Agency awarded a $41,441.33 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, issued on November 7, 2025, with an ultimate completion date of December 2, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The contract represents a single award with no identified subcontractors. DMS Pharmaceutical Group Inc. executes this delivery order under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare operations worldwide. The underlying indefinite delivery contract (SPE2DR) was awarded to DMS Pharmaceutical Group on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The company's established performance on numerous prior delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system across multiple therapeutic categories, including oncology treatments, biologics, vaccines, and specialty pharmaceuticals.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $41.4k | 11/7/25 |